A new Italian phase 4 real-world study named Meporeal has confirmed the efficacy and safety of mepolizumab for treating severe, uncontrolled chronic rhinosinusitis with nasal polyposis (CRSwNP). Published in The Lancet Respiratory Medicine, the research involved 621 patients across 25 specialized centers in Italy. After 12 months of treatment, participants showed significant clinical improvements, including a halving of the median endoscopic severity score from 6 to 3 and a reduction in quality-of-life impact scores from 59 to 21 points. Approximately 42 percent of patients achieved disease control, while around 20 percent met criteria for clinical remission during treatment. The study highlights the drug’s benefits in complex patient populations, where over half had concurrent asthma and many had previously undergone surgery.
Bias read (Center): The article presents neutral medical data and quotes academic experts regarding a specific pharmaceutical trial without using loaded language or taking a political stance.





